Completed PHASE4 INTERVENTIONAL 1-arm NCT01882400

Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy

Évaluation Multidimensionnelle de la réponse au Traitement de l'ostéoporose spontanée et Induite Par Les corticostéroïdes à l'Aide d'un Bisphosphonate à Administration Orale Chez Des Malades Porteurs d'Une Dystrophie Musculaire sévère.

Sponsor: Gilles Boire

Conditions Cystic Fibrosis Muscular Dystrophy Osteoporosis

Interventions Bisphosphonate treatment

Updated 5 times since 2017 Last updated: Jan 6, 2018 Started: May 31, 2001 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01882400, this PHASE4 trial focuses on Cystic Fibrosis and Muscular Dystrophy and remains completed. Sponsored by Gilles Boire, it has been updated 5 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gilles Boire
Procter and Gamble

Data source: Université de Sherbrooke

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sherbrooke, Canada